Towards this aim, we first treated luminal‐type MCF‐7 and T47D breast cancer cells with three HSP90 N‐terminal inhibitors (17‐AAG, AUY922 and STA‐9090) and three HSP90 C‐terminal inhibitors (NB, cisplatin and EGCG) (Figure 1B and Tables S7 and S8).26, 27. Here, HSP90AA1 is linked to breast carcinoma.